INNOVATING BEYOND THE MOLECULE IN BIOPHARMA

1. SEPTEMBER 21, 2017
SHAWN P DAVIS, PHD
INNOVATING BEYOND THE MOLECULE
IN BIOPHARMA
Public Information

2. 2
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
INNOVATING BEYOND THE MOLECULE IN BIOPHARMA
Public Information
Amgen
Introduction
• Startup
success
story
• Molecular
Innovation
Beyond the
Molecule
• Shifts in the
landscape
• Value of an
ecosystem
Case Studies
• Memorial
Sloan
Kettering
• Neulasta®
OnProTM
Kit

3. 3
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
One of the world’s
leading
independent
biotechnology
companies
~ 100 countries
Reached millions
of patients
AMGEN TODAY
Public Information

4. 4
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
THOUSAND OAKS, CALIFORNIA, USA
Photo courtesy of Ed Lawrence
Public Information

5. 5
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
STARTUP
Public Information

6. 6
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
OUR MISSION TO SERVE PATIENTS
Public Information

7. 7
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
FIRST LAUNCHES
Public Information

8. 8
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
PRODUCTS
For additional information about Amgen products, including important safety information, please visit amgen.com
Public Information

9. 9
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
THERAPEUTIC AREAS
Oncology/
Hematology
Cardiovascular
Disease
Inflammation
Bone Health
Neuroscience
Nephrology
Public Information

10. 10
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
FULLY INTEGRATED BIOTECHNOLOGY COMPANY:
WORLD-CLASS CAPABILITIES
Investing in Innovation Protein Engineering
Global Clinical Trials Biologics Manufacturing Successful Launch
Track Record
Global Commercial
Infrastructure
Biology First AdvantageGenetic Validation
Public Information

11. 11
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
OUR STRATEGY
INNOVATIVE MEDICINES
TRANSFORMING AMGEN
FOR THE FUTURE
GLOBAL GEOGRAPHIC
REACH
IMPROVED DRUG
DELIVERY SYSTEMS
CAPITAL ALLOCATION
AND INVESTING FOR
LONG-TERM GROWTH
BRANDED BIOSIMILARS
NEXT-GENERATION
BIOMANUFACTURING
Public Information

12. 12
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
CHANGES IN STRATEGY ARE DRIVEN BY INTERNAL AND
EXTERNAL FORCES
Public Information

13. 13
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
• Randomized, controlled trial: 10 year study following 776 patients treated with
chemotherapy for metastatic cancers
• Patient Reported Outcomes and symptoms via a web portal versus standard of
care
• Five month survivability benefit of the PRO system relative to standard of care
CASE STUDY: ONLINE SYMPTOM-MONITORING TOOL
IMPROVES SURVIVAL FOR METASTATIC CANCER PATIENTS
Public Information
Basch EM, Deal AM, Dueck AC, et al. Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. J
Clin Oncol. 2017;35(suppl; abst LBA2).
“Although symptom management is a cornerstone of high-
quality cancer care, prior research has shown that doctors
miss up to half of patients’ symptoms during cancer
treatment”-Ethan Basch, MD

14. 14
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
What kind of ecosystem is required to support this vision?
• Every patient that can benefit from Amgen’s therapies is
identified, prescribed, and remains adherent to achieve the
full therapeutic benefit of the product.
• The healthcare system fully covers the cost of this care
since the benefit and outcome is known a priori and
confirmed with real world data.
TO SET THE STRATEGY WE MUST HAVE A VISION
In a perfect world…
Public Information

15. 15
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
BEYOND THE MOLECULE INNOVATION
Public Information
“For so long as a company we
thought about innovation as
our molecules. But what we’ve
come to recognize is, that is
not enough. We have to be
innovative in everything we
do… [producing] innovation
beyond the molecule.”
–Amgen CEO Bob Bradway

16. 16
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
AMGEN’S WORLDWIDE INNOVATION NETWORK
Public Information
1. San Jose
2. Santa Monica
3. Cambridge
4. Berlin
5. Tel Aviv
6. Singapore

17. 17
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
The molecule was in the innovation
• NEUPOGEN® helps boost the production of
infection-fighting white blood cells (neutrophils)
• Injected once a day after chemotherapy until
neutrophils return to normal level
CASE STUDY: EVOLUTION OF NEUPOGEN® TO BETTER MEET
PATIENT’S NEEDS
Public Information

18. 18
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
The molecule was the innovation
• Neulasta® is an extended duration form of
NEUPOGEN® to minimize dosing frequency
• Injected once after chemotherapy (must be
administered 24 hours post therapy)
CASE STUDY: EVOLUTION OF NEUPOGEN® TO BETTER MEET
PATIENT’S NEEDS
Public Information

19. 19
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
Drug Delivery becomes the innovation
• The on-body injector for Neulasta® allows the
timing of delivery to eliminate need for patients
to return to the clinic the day after
chemotherapy
– Applied during chemotherapy visit (same day)
– Initiates the Neulasta® delivery 27 hours after
application
CASE STUDY: EVOLUTION OF NEULASTA® TO BETTER MEET
PATIENT’S NEEDS
Public Information

20. 20
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
Digital Health becomes the innovation
• OBI Digital Companion mobile app is an
optional, convenient resource for patients
prescribed Neulasta® OnPro™ Kit
– Provides optional notifications to patient or
caregiver
– Key features are patient education material and
one-touch support
CASE STUDY: EVOLUTION OF NEULASTA® TO BETTER MEET
PATIENT’S NEEDS
Public Information

21. 21
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
• Every patient that can benefit from Amgen’s therapies is
identified, prescribed, and remains adherent to achieve the full
therapeutic benefit of the product.
• The healthcare system fully covers the cost of this care since the
benefit and outcome is known a priori and confirmed with real
world data.
PROGRESS TO ACHIEVE THE VISION IS BEING MADE
In a perfect world…
Public Information

22. 22
Provided September 21, 2017, as part of an oral presentation and is qualified
by such, contains forward-looking statements, actual results may vary
materially; Amgen disclaims any duty to update.
AMGEN’S MISSION IS TO SERVE PATIENTS
Public Information